It's just my opinion, take it or leave it. I'm not going to say "it's outstanding" or "guidance was met" because thats not how I'm interpreting this result. 12 months into sales of Daybue I expected stronger uptake quarter on quarter as news and anecdotes filtered through the Retts community. Pretty unusual to slow down already this early in the piece, but maybe thats a testament to Acadia's sales force doing a great job in pushing the drug to patients.
I don't really know, we'll have to wait for more data as it comes in. But for now you're right, I am hard to please.
Acadia, page-483
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.56 |
Change
-0.400(2.67%) |
Mkt cap ! $1.860B | |||
| Open | High | Low | Value | Volume |
| $14.96 | $15.00 | $14.18 | $7.303M | 503.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 30783 | $14.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.60 | 1006 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |